05Mar 2023
Could Aryl Hydrocarbon Receptor Agonists be the Key to Managing Inflammation in Cystic Fibrosis?

Could Aryl Hydrocarbon Receptor Agonists be the Key to Managing Inflammation in Cystic Fibrosis?

The article discusses the role of hypoxia and aryl hydrocarbon receptor (AhR) in cystic fibrosis (CF) and their potential for anti-inflammatory therapy. Hypoxia contributes to ineffective airway inflammation in CF and inhibiting HIF-1α could impair essential immune functions. The article demonstrates an interferential cross-talk between the AhR and HIF-1α signaling pathways in murine and human CF, where HIF-1α induction impairs the normal AhR response. However, AhR agonism can prevent hypoxia-driven inflammation, restore immune homeostasis, and improve lung function. This study highlights the contribution of environmental factors such as infections in CF disease progression and suggests using hypoxia:xenobiotic receptor cross-talk for anti-inflammatory therapy in CF.

  • #pulmonology

Like

Save

Share